{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"5.08","value":"20.3"},{"groupId":"OG001","spread":"6.35","value":"66.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"43"},{"groupId":"OG001","value":"25"}],"units":"Participants"}],"description":"CHAQ assessed physical ability and functional status of patients as well as quality of life. The disability dimension consisted of 20 multiple choice items about difficulty in doing eight common activities of daily living; dressing and grooming, arising, eating, walking, reaching, personal hygiene, gripping and activities. Four response categories range from 'without any difficulty' (0) to 'unable to do' (3). The parent's or patient's pain assessment was on VAS that was part of CHAQ. The VAS scale ranges from no pain (0 mm) to very severe pain (100 mm). Negative change indicates improvement.","dispersionType":"Standard Error","groups":[{"description":"Patients received a single dose of subcutaneous(sc) injection of canakinumab (4 mg/kg) on Day 1. Maximal total single dose of canakinumab allowed was 300 mg. Any patient who required a dose greater than 150 mg (patients\\>37.5 kg) received two sc injections.","id":"OG000","title":"Canakinumab"},{"description":"Patients received a single dose matching placebo of canakinumab on day 1.","id":"OG001","title":"Placebo"}],"paramType":"LEAST_SQUARES_MEAN","populationDescription":"The Full Analysis Set (FAS) consisted of all randomized patients who received at least one dose of study drug. Only observed cases were used in the analysis.","reportingStatus":"POSTED","timeFrame":"Baseline, Day 15","title":"Change in Patient's Pain Intensity as Assessed on a 100-mm Visual Analog Scale (VAS)as Part of the Childhood Health Assessment Questionnaire(CHAQ)","type":"SECONDARY","unitOfMeasure":"Units on a scale"}